OBJECTIVE Cardiac fibrosis of post-myocardial infarction (MI) is a precipitating factor of diverse cardiac diseases. MicroRNAs (miRNAs) have been reported to be implicated in the progression of cardiac fibrosis, but… Click to show full abstract
OBJECTIVE Cardiac fibrosis of post-myocardial infarction (MI) is a precipitating factor of diverse cardiac diseases. MicroRNAs (miRNAs) have been reported to be implicated in the progression of cardiac fibrosis, but the functions and mechanisms of miR-30b-5p and miR-22-3p remain to be investigated. MATERIALS AND METHODS Cardiac fibroblasts (CFs) were isolated form mice hearts and treated with Angiotensin II (Ang II) for establishing the cardiac fibrosis model of post-MI. The expression of miRNA and mRNA was examined through quantitative real-time polymerase chain reaction (qRT-PCR). Associated protein levels were measured by Western blot. Cell viability was detected via cell counting kit-8 (CCK-8) assay. Dual-Luciferase reporter assay was administered to analyze the target correlation. RESULTS The down-regulation of miR-30b-5p and miR-22-3p while the up-regulation of platelet activating factor receptor (PTAFR) were found in Ang II-treated CFs. Cell proliferation and collagen deposition were refrained by miR-30b-5p and miR-22-3p overexpression and knockdown of PTAFR. MiR-30b-5p and miR-22-3p directly targeted PTAFR. MiR-30b-5p and miR-22-3p inhibitors alleviated the effects on Ang II-treated CFs induced by PTAFR knockdown through promoting PTAFR. CONCLUSIONS MiR-30b-5p and miR-22-3p exerted the suppression of fibrogenesis in Ang II-treated CFs via targeting PTAFR, insinuating the indicative roles of miR-30b-5p and miR-22-3p in the fibrogenesis process.
               
Click one of the above tabs to view related content.